Pediatrix Medical Group, Inc. filings document the public-company disclosures of a Florida physician-services operator focused on obstetrics, maternal-fetal medicine, neonatology and pediatric subspecialty care. Recent Form 8-K reports furnish operating results, including net revenue, earnings measures, same-unit revenue drivers, reimbursement factors, patient volume trends and hospital-based practice activity.
Proxy and governance filings cover director elections, shareholder voting results, executive compensation, pay-versus-performance data and the Pediatrix Medical Group, Inc. Second Amended and Restated 2008 Incentive Compensation Plan. Other material-event reports address board appointments, Regulation FD disclosures and common-stock repurchase authorizations.
Weis Shirley A reported acquisition or exercise transactions in this Form 4 filing.
Pediatrix Medical Group, Inc. reported that director Shirley A. Weis received an equity grant of 472 shares of Common Stock on August 12, 2026. The restricted shares were granted under the company’s Second Amended and Restated 2008 Incentive Compensation Plan and will vest on May 7, 2027. Following this award, Weis directly holds 19,095 shares of Pediatrix Medical Group common stock.
Starcher John M. Jr. reported acquisition or exercise transactions in this Form 4 filing.
Pediatrix Medical Group, Inc. reported that director John M. Starcher Jr. received an equity award of 472 shares of common stock on August 12, 2026. These restricted shares, granted under the company’s Second Amended and Restated 2008 Incentive Compensation Plan, will vest on May 7, 2027. Following this grant, Starcher directly holds 73,732 shares of Pediatrix common stock.
Linynsky Laura A reported acquisition or exercise transactions in this Form 4 filing.
Pediatrix Medical Group director Laura A. Linynsky received a grant of 472 restricted shares of common stock on August 12, 2026 under the company’s Second Amended and Restated 2008 Incentive Compensation Plan, reflecting an increase to her annual equity award. The restricted shares were valued at $26.50 per share for reporting purposes and will vest on May 7, 2027. Following this grant, Linynsky directly holds 39,900 shares of Pediatrix Medical Group common stock.
Newman Kurt Douglas reported acquisition or exercise transactions in this Form 4 filing.
Pediatrix Medical Group director Kurt Douglas Newman received a grant of 472 shares of common stock as a restricted stock award under the company’s Second Amended and Restated 2008 Incentive Compensation Plan. The restricted shares will vest on May 7, 2027, bringing his directly held common stock to 17,405 shares after the award.
Rucker Michael A. reported acquisition or exercise transactions in this Form 4 filing.
Pediatrix Medical Group, Inc. reported that director Michael A. Rucker received an equity compensation grant of 472 shares of common stock at a value of $26.50 per share. These are restricted shares under the Second Amended and Restated 2008 Incentive Compensation Plan and will vest on May 7, 2027. Following this award, Rucker holds 66,769 shares of Pediatrix common stock directly.
Young Sylvia Jean reported acquisition or exercise transactions in this Form 4 filing.
Pediatrix Medical Group, Inc. reported that director Sylvia Jean Young received a grant of 472 restricted shares of common stock on August 12, 2026. The award was granted under the company’s Second Amended and Restated 2008 Incentive Compensation Plan and reflects an increase to her annual equity award. These restricted shares will vest on May 7, 2027, and her directly held common stock position after the grant is 48,286 shares.
SANSONE GUY P reported acquisition or exercise transactions in this Form 4 filing.
Pediatrix Medical Group, Inc. reported that director Guy P. Sansone received an equity award of 472 shares of Common Stock on August 12, 2026. The restricted shares were granted under the Second Amended and Restated 2008 Incentive Compensation Plan and will vest on May 7, 2027, bringing his post-grant direct holdings to 87,416 shares.
Pediatrix Medical Group delivered modest growth for the quarter and six months ended June 30, 2026. Net revenue reached $487.8 million in Q2 and $964.0 million year‑to‑date, both up 4.0% from 2025, driven by acquisitions and same‑unit reimbursement gains, partly offset by lower patient volumes, especially in neonatology.
Q2 income from operations slipped to $56.9 million with an 11.7% operating margin versus 12.8% a year earlier, as practice salaries and benefits and transformational and restructuring costs increased. However, six‑month net income improved to $69.4 million and diluted EPS to $0.85, with Adjusted EBITDA rising to $134.6 million and Adjusted EPS to $1.07.
Cash and cash equivalents fell to $288.9 million, and operating cash flow from continuing operations turned to a $3.2 million use of cash, mainly from incentive compensation and working capital. The company spent $61.7 million repurchasing 2.8 million shares, while maintaining leverage with a $184.4 million Term A Loan, $400.0 million of 2030 Notes and an undrawn $450.0 million revolver. Days sales outstanding improved to 42.5 days, and management expects existing cash, cash generation and credit capacity to cover needs for at least the next 12 months.
Pediatrix Medical Group reported second-quarter 2026 net revenue of $487.8 million, up 4.0% from $468.8 million a year earlier. Net income was approximately $40 million, or diluted EPS of $0.49, while Adjusted EPS was $0.63 and Adjusted EBITDA was about $76 million.
Management attributed growth to 2.1% non-same-unit revenue expansion from recent acquisitions and 1.9% same-unit revenue growth. Same-unit revenue from reimbursement-related factors rose 4.0%, driven by improved cash collections, a more favorable payor mix and higher patient acuity, while same-unit patient volume declined 2.1% and commercial and other non-government payors increased by 135 basis points.
As of June 30, 2026, cash and cash equivalents were $288.9 million, total debt was $584.2 million and shareholders’ equity was $881.0 million. The company also outlined a forward-looking 2026 Adjusted EBITDA range between $280 million and $300 million.
Pediatrix Medical Group, Inc. reports that Mary Ann E. Moore, previously Executive Vice President, General Counsel, Chief Administrative Officer and Secretary, has entered into a Separation Agreement with subsidiary PMG Services, Inc. Under this agreement, she will serve in an advisory role until October 31, 2026, when her employment with the company will end.
The company states that Ms. Moore’s transition is treated as a termination without cause under her Second Amended and Restated Employment Agreement, and she will receive the benefits specified in that agreement. Pediatrix also reports the appointment of David Haddock as Executive Vice President, General Counsel and Secretary.